Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in MEN-1 Neuroendocrine Tumor
NCT06540937Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leflunomide in Neuroendocrine Neoplasm (NEN), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2020; status: recruiting.
02
Drugs
leflunomide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06540937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540937.